What is the mechanism of action for Raloxifene (Evista) in relation to bone health?

• A. Acts as an estrogen antagonist on bone
• B. Acts as an estrogen agonist on bone
• C. Inhibits bone mineral density
• D. Promotes osteoclast formation

Answer: (B)

Raloxifene (Evista) is classified as a selective estrogen receptor modulator (SERM), meaning that it acts as an estrogen agonist in certain tissues, including bone. This agonistic action on bone leads to a decrease in bone resorption and helps maintain or increase bone mineral density. By mimicking the positive effects of estrogen on bone tissue, Raloxifene can therefore reduce the risk of osteoporosis and fractures in postmenopausal women.

Estrogen has a well-documented protective effect on bone health, as it inhibits the activity of osteoclasts, the cells responsible for bone resorption. By acting as an estrogen agonist, Raloxifene effectively exerts similar protective actions, enhancing bone density and supporting overall bone health. Understanding this mechanism is crucial for recognizing how Raloxifene fits into the management of osteoporosis.